EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
- Resource Type
- Abstract
- Source
- In
Value in Health December 2022 25(12) Supplement:S168-S168 - Subject
- Language
- ISSN
- 1098-3015